gsk2256098 and Meningioma

gsk2256098 has been researched along with Meningioma* in 1 studies

Trials

1 trial(s) available for gsk2256098 and Meningioma

Article	Year
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-20, Volume: 41, Issue:3 Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with. GSK2256098 was well tolerated and resulted in an improved PFS6 rate in patients with recurrent or progressive Topics: Focal Adhesion Protein-Tyrosine Kinases; Humans; Meningeal Neoplasms; Meningioma; Mutation; Neoplasm Recurrence, Local	2023

Article

Year

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-20, Volume: 41, Issue:3

Patients with progressive or recurrent meningiomas have limited systemic therapy options. Focal adhesion kinase (FAK) inhibition has a synthetic lethal relationship with. GSK2256098 was well tolerated and resulted in an improved PFS6 rate in patients with recurrent or progressive

Topics: Focal Adhesion Protein-Tyrosine Kinases; Humans; Meningeal Neoplasms; Meningioma; Mutation; Neoplasm Recurrence, Local

2023